Rallybio is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The company continues to build a portfolio of product candidates with the potential to eradicate or transform rare diseases.
At Rallybio, we are building a portfolio of product candidates that target devastating rare disorders with significant morbidity and mortality. Each product candidate must also meet the following criteria:
Therapeutic has potential for transformative clinical and functional impact
Therapeutic is an engineered protein, antibody or small molecule
Therapeutic is late discovery to early clinical stage
Target Disease has Well Understood Pathophysiology
Target Disease affects >3 patients per million